The anticipation of regulatory approvals for new vaccines, especially for older adults, can lead to positive investor sentiment, as it opens up new revenue streams. Additionally, achieving key milestones in the late-stage pipeline demonstrates the company's ongoing innovation and potential for future growth, both of which are critical factors that investors consider when evaluating a biotech company's stock.